ストックスクリーナーアプリを入手
8.32
4.70%
-0.41
アフターアワーズ：
8.68
0.36
+4.33%
前日終値:
$8.73
開ける：
$8.69
24時間の取引高:
186.43K
Relative Volume:
0.79
時価総額：
$114.48M
収益：
-
当期純損益:
$-56.20M
株価収益率:
-2.3305
EPS:
-3.57
ネットキャッシュフロー:
$-39.97M
1週間 パフォーマンス:
-14.67%
1か月 パフォーマンス:
-1.07%
6か月 パフォーマンス:
+60.62%
1年 パフォーマンス:
+30.61%
1日の値動き範囲:
$8.22
$8.8121
1週間の範囲:
$8.22
$9.78
52週間の値動き範囲:
$4.53
$22.49
Annovis Bio Inc Stock (ANVS) Company Profile
名前
Annovis Bio Inc
セクター
電話
484-875-3192
住所
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-07-07 | 繰り返されました | Maxim Group | Buy |
Annovis Bio Inc (ANVS) 最新ニュース
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio - GlobeNewswire
Annovis Bio, Inc. (NYSE:ANVS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Annovis Bio (NYSE:ANVS) Raised to Buy at Maxim Group - MarketBeat
Annovis Bio to Present Key Alzheimer’s Research at CTAD Conference - MSN
Annovis Bio (NYSE: ANVS) Receives FDA Clearance to Initiate Pivotal Phase 3 Alzheimer’s Studies - Barchart
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024 - The Manila Times
Annovis Bio files three drug patents - Pennsylvania Business Report
Annovis Bio: Funding May Be An Issue For Announced Phase 3 Trials (NYSE:ANVS) - Seeking Alpha
Annovis Bio To Continue Alzheimer's Disease Clinical Trials (NYSE:ANVS) - Seeking Alpha
Annovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug - Yahoo Finance
Annovis Bio shares hold Buy rating from HC Wainwright - Investing.com India
Annovis Bio Stock Surges As Analyst Reiterates ‘Buy’ On Alzheimer’s Drug Progress: Retail Stays Bullish - Barchart
Annovis Bio shares hold Buy rating from HC Wainwright By Investing.com - Investing.com UK
In the Green: Annovis Bio Inc (ANVS) Closes at 7.98, Up/Down 6.26 from Previous Day - The Dwinnex
Annovis Bio (NYSE:ANVS) Given Buy Rating at HC Wainwright - MarketBeat
(ANVS) Investment Analysis and Advice - Stock Traders Daily
Annovis Bio Advances Alzheimer’s Treatment with FDA Approval for Phase 3 Trials - MyChesCo
Annovis Bio (ANVS) Stock Soars After FDA Approval - Stocks Telegraph
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs - The Manila Times
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs - GlobeNewswire
Freedom Village Hosts Successful Third Annual Walk to End Alzheimer’s - MyChesCo
(ANVS) On The My Stocks Page - Stock Traders Daily
Annovis Bio Inc (ANVS-N) QuotePress Release - The Globe and Mail
ANVSAnnovis Bio, Inc. Latest Stock News & Market Updates - StockTitan
Brookline Capital Initiates Coverage of Annovis Bio (ANVS) with Buy Recommendation - MSN
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases - ForexTV.com
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for ... - The Bakersfield Californian
Annovis Bio, Inc. (NYSE:ANVS) Receives Average Rating of "Buy" from Analysts - MarketBeat
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Three Patents Covering Combination Therapies for AD, PD - MSN
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations - The Manila Times
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential - GlobeNewswire
19,907 Shares in Annovis Bio, Inc. (NYSE:ANVS) Bought by XTX Topco Ltd - Defense World
Annovis Bio Files Patents for Innovative Therapies in Neurodegenerative Disease Treatment - MSN
Annovis Bio stock outlook supported by innovative neurodegenerative therapies - Investing.com India
Annovis Bio: Against The Grain In Alzheimer's Disease - Life Science Leader Magazine
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition - cnhinews.com
Annovis Bio (NYSE:ANVS) Rating Reiterated by HC Wainwright - MarketBeat
Annovis Bio files three new patents for combination therapies - TipRanks
Annovis Bio files patents for neurodegenerative treatment combos - Investing.com
Annovis Bio Files Patents for Neurodegenerative Combination Therapies - TipRanks
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra - GlobeNewswire
Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom - Seeking Alpha
Anavex Lf SC (AVXL-Q) QuotePress Release - The Globe and Mail
Longeveron Inc (LGVN-Q) QuotePress Release - The Globe and Mail
(ANVS) Long Term Investment Analysis - Stock Traders Daily
Passage Bio Shares Promising Data on PBFT02 for Frontotemporal Dementia - MyChesCo
Annovis Bio Inc (ANVS) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):